NEW YORK (GenomeWeb News) – Abbott today reported that its second-quarter molecular diagnostics sales increased around 19 percent year over year.
The firm posted total molecular diagnostics sales of $105 million for the three-month period ended June 30, compared to $89 million for Q2 2010. Of the $105 million, $45 million of the sales came from the US with the remainder coming from international markets.
The firm reiterated its plans to launch more than 12 new molecular diagnostics products, including oncology and infectious disease assays, over the next few years. It noted that it has submitted for regulatory clearance an ALK gene rearrangement test for non-small cell lung cancer to be used in combination with Pfizer's crizotinib.
Overall, Abbott reported Q2 sales of $9.62 billion, up 9 percent from $8.83 billion for the prior-year second quarter. Its net earnings rose to $1.94 billion, or $1.23 per share, from $1.29 billion, or $.83 per share.